The UK’s independent Parliamentary Office of Science and Technology (POST) has issued a rapid response on psychedelic-assisted therapy for anxiety disorders.
The European Medicines Agency (EMA) is set to hold a multi-stakeholder workshop on medical psychedelics in April 2024 to establish regulatory guidelines for the development and...
The Psychedelic Access and Research European Alliance (PAREA) has launched a policy paper in line with a recent meeting on medical psychedelics in the European Parliament.
Activists in Oakland have filed a ballot that seeks to legalise safe and legal access to psychedelics for therapeutic uses.
A new initiative, the PsychedeliCare Initiative, will launch in 2024 to bring citizens together to educate about psychedelics, call for the reshaping of drug policy and...
The European Medicines Agency (EMA) has updated its general guidelines on the development of medicinal products for Major Depressive Disorder (MDD) to include a section on...
In a new policy briefing for the European Medicines Agency (EMA), Psychedelic Access and Research European Alliance (PAREA) has called for an advisory body on psychedelics...
In the latest development for psychedelics in the UK, the Home Affairs Committee Drug Report has seen MPs call for a review of drug scheduling in...
With a rise in clinical trials investigating psychedelics for a number of mental health conditions, the UK’s Parliamentary Office of Science and Technology (POST) has issued...
The Psychedelic Access and Research Alliance (PAREA) has released a position statement calling on the EU to harness psychedelics in a bid to create innovation in...